BeOne Medicines (BEIGF) EPS (Basic) Growth (1y) (2016 - 2026)
Powered by 
Analysis
BeOne Medicines (BEIGF) EPS (Basic) Growth (1y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.71 Bn | 625.95 Bn | 17.26 Bn | -0.10% |
| 2 | AbbVie | 442.22 Bn | 435.65 Bn | 12.70 Bn | 284.05% |
| 3 | Merck | 366.92 Bn | 359.78 Bn | 12.21 Bn | -130.68% |
| 4 | Novartis Ag | 266.90 Bn | 259.21 Bn | 11.24 Bn | -15.94% |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | -108.11% |
| 6 | Sanofi | 52.44 Bn | 45.06 Bn | 10.79 Bn | -91.06% |
| 7 | Revolution Medicines | 44.11 Bn | 44.11 Bn | - | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 39.99% |
| 9 | United Therapeutics | 21.50 Bn | 18.84 Bn | 683.80 Mn | 13.91% |
| 10 | BeOne Medicines | 2.48 Bn | -2.62 Bn | 1.53 Bn | 143.95% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 143.95% |
| Mar 31, 2026 | 17,151.81% |
| Dec 31, 2025 | 142.27% |
| Sep 30, 2025 | 198.85% |
| Jun 30, 2025 | 175.72% |
| Mar 31, 2025 | 100.49% |
| Dec 31, 2024 | 59.03% |
| Sep 30, 2024 | -155.68% |
| Jun 30, 2024 | 68.43% |
| Mar 31, 2024 | 27.99% |
| Dec 31, 2023 | 18.46% |
| Sep 30, 2023 | 138.20% |
| Jun 30, 2023 | 33.81% |
| Mar 31, 2023 | 21.25% |
| Dec 31, 2022 | 32.17% |
| Sep 30, 2022 | -14.08% |
| Jun 30, 2022 | -5.23% |
| Mar 31, 2022 | -684.18% |
| Dec 31, 2021 | -6.13% |
| Sep 30, 2021 | 2.16% |